ArticleThe Journal of experimental medicine2021
Broadly neutralizing monoclonal antibodies protect against multiple tick-borne flaviviruses.
Article in The Journal of experimental medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 31 citations in OpenAlex.
- Protective human antibodies against Powassan virus.Journal of virology · 2026Article
- Screening pertactin-specific antibodies and evaluating competitive epitope recognition by native mass spectrometry.Chemical science · 2026Article
- Tick-Borne Co-Infection in Lyme Disease: Clinical Impact, Diagnostic Challenges, and Therapeutic Perspectives.Microorganisms · 2026Review
- LRP8 is an entry receptor for tick-borne encephalitis viruses.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Mass Spectrometry-Based Protein Footprinting for Protein Structure Characterization.Accounts of chemical research · 2025Article
- Animal Models, Therapeutics, and Vaccine Approaches to Emerging and Re-Emerging Flaviviruses.Viruses · 2024Review
- Neurological Complications Associated With the Powassan Virus and Treatment Interventions.Cureus · 2024Review
- Prevalence of Powassan Virus Seropositivity Among People with History of Lyme Disease and Non-Lyme Community Controls in the Northeastern United States.Vector borne and zoonotic diseases (Larchmont, N.Y.) · 2024Article
- Tick-Borne Encephalitis-Review of the Current Status.Journal of clinical medicine · 2023Review
- T Cells in Tick-Borne Flavivirus Encephalitis: A Review of Current Paradigms in Protection and Disease Pathology.Viruses · 2023Review
- Dynamics of SARS-CoV-2 VOC Neutralization and Novel mAb Reveal Protection against Omicron.Viruses · 2023Article
- Hydrogen Deuterium Exchange and other Mass Spectrometry-based Approaches for Epitope Mapping.Frontiers in analytical science · 2023Article
- Cross-Reactive Antibodies in Tick-Borne Encephalitis: Case Report and Literature Review.Antibodies (Basel, Switzerland) · 2022Article
- Can Modern Molecular Modeling Methods Help Find the Area of Potential Vulnerability of Flaviviruses?International journal of molecular sciences · 2022Article
- A Powassan virus domain III nanoparticle immunogen elicits neutralizing and protective antibodies in mice.PLoS pathogens · 2022Article
- Neutralizing antibodies protect mice against Venezuelan equine encephalitis virus aerosol challenge.The Journal of experimental medicine · 2022Article
- Balanced T and B cell responses are required for immune protection against Powassan virus in virus-like particle vaccination.Cell reports · 2022Article
- Powassan Viruses Spread Cell to Cell during Direct Isolation fromJournal of virology · 2022Article
- Serological cross-reactivity among common flaviviruses.Frontiers in cellular and infection microbiology · 2022Review
- A pigtailed macaque model of Kyasanur Forest disease virus and Alkhurma hemorrhagic disease virus pathogenesis.PLoS pathogens · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 3 institutions in 1 country.
Funding
Abstract
Although Powassan virus (POWV) is an emerging tick-transmitted flavivirus that causes severe or fatal neuroinvasive disease in humans, medical countermeasures have not yet been developed. Here, we developed a panel of neutralizing anti-POWV mAbs recognizing six distinct antigenic sites. The most potent of these mAbs bind sites within domain II or III of the envelope (E) protein and inhibit postattachment viral entry steps. A subset of these mAbs cross-react with other flaviviruses. Both POWV type-specific and cross-reactive neutralizing mAbs confer protection in mice against POWV infection when given as prophylaxis or postexposure therapy. Several cross-reactive mAbs mapping to either domain II or III also protect in vivo against heterologous tick-transmitted flaviviruses including Langat and tick-borne encephalitis virus. Our experiments define structural and functional correlates of antibody protection against POWV infection and identify epitopes targeted by broadly neutralizing antibodies with therapeutic potential against multiple tick-borne flaviviruses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.